medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 3

<< Back Next >>

Ann Hepatol 2003; 2 (3)

Hepatic encephalopathy: A review

Lizardi-Cervera J, Almeda P, Guevara L, Uribe M

Language: English
References: 31
Page: 122-130
PDF size: 111.24 Kb.


Text Extraction

Hepatic encephalopathy (HE) is a complication that presents in as many as 28% of patients with cirrhosis, and reported up to ten years after the diagnosis of cirrhosis. Commonly, it is observed in patients with severe hepatic failure and is characterized by neuropsychiatric manifestations that can range in severity from a mild alteration in mental state to a coma; additionally, some neuromuscular symptoms can be observed. This complication of either acute or chronic hepatic disease is the result of a diminished hepatic reservoir and inability to detoxify some toxins that originate in the bowel. Today, the role of astrocytes, specifically the Alzheimer type II cells, is known to be very important in the pathogenesis of the hepatic encephalopathy, and will be reviewed later.

In conclusion, the objectives of this review are:
• To understand the pathogenesis of hepatic encephalopathy
• To recognize the precipitating factors, as well as preventive measures for the development of the hepatic encephalopathy
• To describe the new classification of hepatic encephalopathy and its clinical implications
• To recognize the clinical manifestations and stages of the disease
• To understand the main diagnostic tests used to detect the hepatic encephalopathy
• To describe the main therapeutic treatments of hepatic encephalopathy.


REFERENCES

  1. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997; 92: 1429-39.

  2. Adams RD, Foley JM. The neurological disorder associated with liver disease. Proc Ass Res Nerv Dis 1953; 32: 198-237.

  3. Sobukawa E, Sakimura K, Hoshino S, Hoshino M, Miyoshi K. Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Internal Medicine 1994; 33: 718-22.

  4. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984; 2: 493-5.

  5. Blei AT. Helicobacter pylori, harmful to the brain? Gut 2001; 48: 590-1.

  6. Bustamante J, Rimola A, Ventura P, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.

  7. Powell EE, Pender MP, Chalk JB, Parkin PJ, Strong R, Lynch S, et al. Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology 1990; 98: 1079-82.

  8. Plauth M, Merli M, Kondrup J. Management of hepatic encephalopathy. N Eng J Med 1997; 337: 1921-2.

  9. Plauth M, Merli M, Weimann A, Ferenci P, Mueller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clinical Nutrition 1997; 16: 43-55.

  10. Felipo V, Miñana D, Grisolia S. Control of urea synthesis and ammonia utilization in protein deprivation and refeeding. Arch Biochem Biophys 1991; 285: 351-6.

  11. Vilstrup H. Synthesis of urea after stimulation with amino acids: relation to liver function. Gut 1980; 21: 990-5.

  12. Lockwood AH, McDonald JM, Rieman RE, Gelbard AS, Laughlin JS, Duffy TE, et al. The dynamics of ammonia metabolism in men. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.

  13. Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279-87.

  14. Bianchi GP, Marchesini G, Fabbri A, Rondelli A, Bugianesi E, Zoli M, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993; 233: 385-92.

  15. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein- controlled trial. J Hepatol 1990; 11: 92-101.

  16. Morgan MY. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies. J Hepatol 1990; 11: 133-41.

  17. Weber FL, Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982; 82: 213-7.

  18. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987; 4: 236-44.

  19. Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G, et al. Association lactulose-neomycine versus placebo dans le traitement de l’encephalopathie hepatique aigue. Resultats d’un essai controle randomise. Gastroenterol Clin Biol 1994; 18: 1063-8.

  20. van Berlo CL, van Leeuwen PA, Soeters PB. Porcine intestinal ammonia liberation. Influence of food intake, lactulose and neomycin. J Hepatol 1988; 7: 250-7.

  21. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406.

  22. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980; 78: 663-70.

  23. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640-4.

  24. Uribe M, Farca A, Marquez MA. Treatment of chronic portal systemic encephalopathy with bromocriptine: A double blind controlled trial. Gastroenterology 1979; 76: 1347-51.

  25. Uribe M, Campollo A, Vargas F. Acidifying enemas (lactitol and lactosa) vs non acidifying enemas (tap water)to treat acute portal systemic encephalopathy: A double blind randomized clinical trial. Hepatology 1987; 7: 639-43.

  26. Uribe M, Berthier JM, Lewis H. Lactosa enemas plus placebo tablets vs neomycin tablets plus starch enemas in acute portal systemic ecephalopathy. A double blind randomized controlled study. Gastroenterology 1981; 81:101-6

  27. Uribe M, Morán S, Poo JL, Muñoz R. In Vitro and in Vivo Lactose and Lactulose. Effects on Colonic Fermentation and Portal-systemic Encephalopathy Parameters. Scand J Gastroenterol 1997; 32 Suppl 222: 49-52.

  28. Blei T. Andres. Hepatic Encephalopathy. In Complication on Cirrhosis: Pathogenesis, Consequences and Therapy. AASLD. Liver Meeting 2001; 131-134.

  29. Uribe M, Morán S, Poo JL, Méndez-Sánchez N, Guevara L, García-Ramos G. Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. Scand J Gastroenterol 1998; 33: 1099-106.

  30. Hepatic encephalopathy- Definition, nomenclature, diagnosis and quantification: Final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.

  31. Mullen KD. Treatment of Hepatorenal syndrome. Lessons from the MARS trial. Hepatology 2002; 35(2): 492-93.




2020     |     www.medigraphic.com